TITLE

Recent advancements in oxadiazole-based anticancer agents

AUTHOR(S)
Rasool, Irfan; Ahmad, Matloob; Khan, Zulfiqar Ali; Mansha, Asim; Maqbool, Tahir; Zahoor, Ameer Fawad; Aslam, Sana
PUB. DATE
March 2017
SOURCE
Tropical Journal of Pharmaceutical Research;Mar2017, Vol. 16 Issue 3, p723
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Oxadiazole ring system occupies a significant position among heterocyclic templates for medicinal compounds due to its wide spectrum of biological activities. This article entails an in-depth review of the ability of oxadiazole derivatives to induce apoptosis of cancer cells. FDA has approved a number of drugs for the treatment of different types of cancer. There is, however, a continuing need for the development of new anticancer agents due to increasing cases of drug resistance. Moreover, medicinal chemists are continuously struggling to invent selective cytotoxic agents with minimum side effects. This work reviews the significance of oxadiazole ring system and its potential to act as a template for novel anticancer agents.
ACCESSION #
122475688

 

Related Articles

  • Recent Advances in Multidrug Resistance Modulators. Avendaño, Carmen; Menéndez, J. Carlos // Medicinal Chemistry Reviews - Online;Oct2004, Vol. 1 Issue 4, p419 

    Multidrug resistance (MDR) is a type of resistance to structurally unrelated chemotherapeutic drugs, and is one of the main obstacles in the chemotherapy of cancer, malaria and other diseases. In the case of cancer, its inhibition by combination of chemosensitizers with antitumor compounds...

  • The roles of copper transporters in cisplatin resistance. Macus Kuo; Im-Sook Song; Niramol Savaraj; Toshihisa Ishikawa // Cancer & Metastasis Reviews;Mar2007, Vol. 26 Issue 1, p71 

    Abstract  Platinum-based antitumor agents have been effective in the treatments of many human malignancies but the ultimate success of these agents is often compromised by development of drug resistance. One mechanism associated with resistance to platinum drugs is reduced intracellular...

  • This breast cancer drug is first in new class of chemo agents. Belden, Heidi // Drug Topics;12/10/2007, Vol. 151 Issue 23, p18 

    The article reports that the U.S. Food & Drug Administration has approved the anti-breast cancer agent ixabepilone from Bristol-Myers Squibb both as monotherapy and in combination with capecitabine. According to the author, the anticancer agent is indicated in patients with metastatic or locally...

  • Bayer/Onyx Pharmaceuticals: Nexavar approved for kidney cancer in Japan.  // PharmaWatch: Monthly Review;Mar2008, Vol. 7 Issue 3, p7 

    The article reports on the approval of Nexavar drug from Bayer and Onyx Pharmaceuticals to treat renal cell carcinoma in Japan. The approval makes Nexavar the first oral targeted therapy to be granted in the pharmaceutical market. It will advance the outcomes of patients affected with renal cell...

  • GlaxoSmithKline: Cervarix enters potentially lucrative cervical cancer prevention market.  // PharmaWatch: Monthly Review;Nov2007, Vol. 6 Issue 11, p7 

    The article reports on the announcement made by GlaxoSmithKline regarding the approval of its Cervarix, a vaccine that prevents cervical cancer, by the European Union (EU). According to the article, the vaccine provides 100% protection against cancer wounds caused by human papillomavirus (HPV)....

  • Novartis: heeding the shift in the cancer treatment paradigm.  // PharmaWatch: Cancer;May2006, Vol. 5 Issue 5, p13 

    The article reports that Novartis AG has filed for marketing approval for Gleevec, a drug used in treating chronic myelogenous leukemia, gastrointestinal stromal tumors and a number of other malignancies in both the U.S. and Europe. The company seeks an approval based on the positive clinical...

  • A Meta analysis assessment colorectal cancer in-patient to limited data of bevacizumab in decide therapy with. Rubbal, Fabiana; Panico, Salvatore; Cuccaro, Patrizia; Della Vecchia, Antonio; Triassi, Maria // Cancer Therapy;2008, Vol. 6 Issue 2, p617 

    We evaluated the introduction of a new targeting antineoplastic drug, Bevacizumab, for a young woman and for almost 30 in - patients of Federico II University Hospital, Naples, the year when this drug was approved for treatment in Europe, by summoning systematic reviews to a multidisciplinary...

  • Gene Directed Enzyme Prodrug Therapy for Ovarian Cancer: Could GDEPT Become a Promising Treatment Against Ovarian Cancer? Nawa, Akihiro; Tanino, Tadatoshi; Luo, Chen H.; Iwaki, Masahiro; Kajiyama, Hiroaki; Shibata, Kiyosumi; Yamamoto, Eiko; Ino, Kazuhiko; Nishiyama, Yukihiro; Kikkawa, Fumitaka // Anti-Cancer Agents in Medicinal Chemistry;2008, Vol. 8 Issue 2, p232 

    Gene-directed enzyme prodrug therapy (GDEPT) involves the treatment concept of having maximal efficacy and minimal adverse effects. Several GDEPT strategies have been developed combining cytosine deaminase and 5-fluorocytosine, cytochrome P450 2B1 and cyclophosphamide, and carboxylesterase (CES)...

  • Metabolism of the Novel IMP Dehydrogenase Inhibitor Benzamide Riboside. Jäger, Walter; Salamon, Alexandra; Szekeres, Thomas // Medicinal Chemistry Reviews - Online;Apr2004, Vol. 1 Issue 2, p225 

    Benzamide riboside (BR) is a novel anticancer agent exhibiting pronounced activity against several human tumor cell lines via the inhibition of inosine 5'-monophosphate dehydrogenase (IMPDH) that catalyzes the formation of xanthine 5'-monophosphate from inosine 5'-monophosphate and nicotinamide...

  • Structure-guided design of a selective BCL-XL inhibitor. Lessene, Guillaume; Czabotar, Peter E; Sleebs, Brad E; Zobel, Kerry; Lowes, Kym N; Adams, Jerry M; Baell, Jonathan B; Colman, Peter M; Deshayes, Kurt; Fairbrother, Wayne J; Flygare, John A; Gibbons, Paul; Kersten, Wilhelmus J A; Kulasegaram, Sanji; Moss, Rebecca M; Parisot, John P; Smith, Brian J; Street, Ian P; Yang, Hong; Huang, David C S // Nature Chemical Biology;Jun2013, Vol. 9 Issue 6, p390 

    The prosurvival BCL-2 family protein BCL-XL is often overexpressed in solid tumors and renders malignant tumor cells resistant to anticancer therapeutics. Enhancing apoptotic responses by inhibiting BCL-XL will most likely have widespread utility in cancer treatment and, instead of inhibiting...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics